PREP — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL167216	0.57	13/20
SCHEMBL301874	0.47	11/20
SCHEMBL664896	0.54	9/20
SCHEMBL664897	0.54	9/20
SCHEMBL665308	0.47	9/20
SCHEMBL665317	0.47	9/20
SCHEMBL298574	0.54	8/20
SCHEMBL666567	0.51	8/20
SCHEMBL666568	0.51	8/20
SCHEMBL665438	0.49	8/20
SCHEMBL665439	0.49	8/20
SCHEMBL666982	0.49	8/20
SCHEMBL666983	0.49	8/20
SCHEMBL666254	0.47	8/20
SCHEMBL666993	0.47	8/20
Berberine (SCHEMBL25632)	0.77	7/20
Berberine (SCHEMBL220544)	0.76	7/20
Berberine (SCHEMBL231931)	0.72	7/20
Berberine (SCHEMBL94112)	0.71	7/20
SCHEMBL666480	0.69	7/20

Clinical trials — most relevant to PREP by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age	PHASE4	COMPLETED
A Study of Elaprase in Children and Adults With Hunter Syndrome (Mucopolysaccharidosis II) in India	PHASE4	COMPLETED
Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor)	PHASE4	COMPLETED
AN-PEP on Gluten Exposure in Celiacs	PHASE4	COMPLETED
Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease	PHASE4	COMPLETED
Treatment Frequency Reduction in Pompe Disease	PHASE4	NOT_YET_RECRUITING
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.	PHASE4	RECRUITING
Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults	PHASE3	COMPLETED
A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents	PHASE3	ACTIVE_NOT_RECRUITING
Aralast NP With Antiviral Treatment and Standard of Care Versus Antiviral Treatment With Standard of Care in Hospitalized Patients With Pneumonia and COVID-19 Infection	PHASE3	WITHDRAWN
Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in Heart Failure With Preserved Ejection Fraction	PHASE3	WITHDRAWN
Roflumilast in Non-CF Bronchiectasis Study (2019)	PHASE2	COMPLETED
Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients	PHASE2	WITHDRAWN
Effect of Aspergillus Niger Prolyl Endoprotease (AN-PEP) Enzyme on the Effects of Gluten Ingestion in Patients With Coeliac Disease	PHASE1/PHASE2	COMPLETED
Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus	PHASE2	COMPLETED
An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment	PHASE1/PHASE2	COMPLETED
Zemaira Eosinophilic Esophagitis Pilot Study	PHASE2	RECRUITING
Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease	PHASE1	COMPLETED
Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma	EARLY_PHASE1	ACTIVE_NOT_RECRUITING
Ovarian Reserve and Matrix Metalloproteinases	nan	COMPLETED
Serum Prolidase Activity and the Role of Leptin in Osteomalacia	nan	UNKNOWN
Prolidase Enzyme Activity in Stroke Patients	nan	COMPLETED
Genetic Mechanisms of Chronic Obstructive Pulmonary Disease (COPD)	nan	COMPLETED
Clearance of Vasoactive Metabolites With Blood Purification	nan	RECRUITING
Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients	nan	APPROVED_FOR_MARKETING
DPP4 Activity, Microvascular Reactivity and Inflammation	nan	COMPLETED
Effect of Microbial Protease Supplementation on Postprandial Amino Acid Levels	nan	COMPLETED
Predictive Values of Presepsin Levels in ASciteS in Patients With Chronic Liver Failure	nan	RECRUITING
PREPL in Health and Disease	nan	ACTIVE_NOT_RECRUITING
Proteolytic Enzyme Fortified Protein Supplement in Chronic Pancreatitis.	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a PREP binder may also engage these)

Protein	Name	Similarity
P23687	—	1.000	P23687 →
O70196	—	1.000	O70196 →
Q9QUR6	—	1.000	Q9QUR6 →
Q9XTA2	—	1.000	Q9XTA2 →
A0A0K9RL25	—	0.951	A0A0K9RL25 →
DPP9	Dipeptidyl peptidase 9	0.950	landscape →
Q5RFI8	—	0.948	Q5RFI8 →
Q28BL6	—	0.947	Q28BL6 →
E0CSI1	—	0.946	E0CSI1 →
Q5RDD3	—	0.946	Q5RDD3 →
B9N1F9	—	0.944	B9N1F9 →
Q9D020	—	0.943	Q9D020 →
B4G0F3	—	0.943	B4G0F3 →
Q16134	—	0.943	Q16134 →
Q8R127	—	0.943	Q8R127 →
Q08DP0	—	0.943	Q08DP0 →
Q8BVG4	—	0.942	Q8BVG4 →
Q9FN41	—	0.942	Q9FN41 →
ACSL1	Long-chain-fatty-acid--CoA ligase 1	0.942	landscape →
Q5R514	—	0.942	Q5R514 →
Q7TSV4	—	0.942	Q7TSV4 →
Q2R483	—	0.942	Q2R483 →
O80840	—	0.941	O80840 →
Q5ZMA6	—	0.941	Q5ZMA6 →
Q64514	—	0.941	Q64514 →
P13221	—	0.941	P13221 →
PGM2	Phosphopentomutase	0.941	landscape →
O24653	—	0.941	O24653 →
TPP2	Tripeptidyl-peptidase 2	0.941	landscape →
Q98SL0	—	0.940	Q98SL0 →